AstraZeneca Archives -

FDA approves AZ’s Farxiga in new heart failure prevention use

The FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in

FDA approves AZ’s Farxiga in new heart failure prevention use

https://pharmaphorum.com/news/fda-approves-azs-farxiga-in-new-heart-failure-prevention-use/

AZ/Daiichi’s possible breast cancer blockbuster gets fast US review

The FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan,

AZ/Daiichi’s possible breast cancer blockbuster gets fast US review

https://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

https://pharmaphorum.com/news/imaginab-joins-with-az-pfizer-and-takeda-to-develop-tumour-imaging-tech/

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

AZ sells rights to gastro drug Losec to Cheplapharm in $309m deal

AstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands

AZ sells rights to gastro drug Losec to Cheplapharm in $309m deal

https://pharmaphorum.com/news/az-sells-rights-to-gastro-drug-losec-to-cheplapharm/

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

https://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

https://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

GlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

https://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/

The Pharma Comms Impact Conference – For Internal & External

20 Pharmaceutical Communications Senior Speakers, 1 Day

The Pharma Comms Impact Conference – For Internal & External

https://pharmaphorum.com/events/the-pharma-comms-impact-conference-for-internal-external/

Trending

AstraZeneca

Hello World

FDA approves AZ’s Farxiga in new heart failure prevention use

AZ/Daiichi’s possible breast cancer blockbuster gets fast US review

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

ESMO 2019 roundup

AZ sells rights to gastro drug Losec to Cheplapharm in $309m deal

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

The Pharma Comms Impact Conference – For Internal & External

Search

Advanced Search

Trending

AstraZeneca

Hello World